La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
95 hedge funds and large institutions have $828M invested in La Jolla Pharmaceutical Company in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
15% more capital invested
Capital invested by funds: $718M → $828M (+$111M)
14% more funds holding
Funds holding: 83 → 95 (+12)
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
88% less call options, than puts
Call options by funds: $5.35M | Put options by funds: $44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$13.5M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.58M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.26M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$25.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$14M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$11.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.62M |
| 5 |
BC
Broadfin Capital
New York
|
-$6.42M |
LJPC Hedge Fund Activity: Q3 2017 in Review
95 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2017, worth a combined $828M — up 15% from $718M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LJPC positions and 10 closed out — a net gain of 14 holders — while 29 added to existing stakes and 26 trimmed.
The largest buyer was Oak Ridge Investments, opening a new position worth an estimated $13.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $25.2M sold.
- 95 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2017, up from 83 in Q2 2017.
- Funds reported $828M of La Jolla Pharmaceutical Company stock for Q3 2017, up 15% quarter-over-quarter.
- 24 funds opened new La Jolla Pharmaceutical Company positions in Q3 2017 and 10 closed out, a net change of +14 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q3 2017 was Oak Ridge Investments, an estimated $13.5M added.
- The largest La Jolla Pharmaceutical Company seller in Q3 2017 was Janus Henderson Group, an estimated $25.2M sold.
Based on aggregated 13F filings for Q3 2017.